Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.56 |
| ▸ | CES1 | P23141 | 3/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21207989 | 0.84 | CES2 (0.41) | CES2CES1CA3CA6CA5A | |
| SCHEMBL29727310 | 0.82 | CES2 (0.56) | CES2CES1CA3CA6CA5A | |
| SCHEMBL13689710 | 0.82 | CES2 (0.56) | CES2CES1CA3CA6CA5A | |
| SCHEMBL16960709 | 0.81 | CES2 (0.60) | CES2CES1CA3CA6CA5A | |
| SCHEMBL19859386 | 0.80 | CLK1 (0.40) | CES2CES1CA3CA6CA5A | |
| SCHEMBL15177920 | 0.80 | NFE2L2 (0.39) | CES2CES1ALDH1A1TSHRMAPK1 | |
| SCHEMBL10290613 | 0.80 | CA3 (0.43) | CES2CES1CA3CA6CA5A | |
| SCHEMBL15172864 | 0.80 | CES2 (0.39) | CES2CES1CA3CA6CA5A | |
| SCHEMBL16959306 | 0.79 | CES2 (0.58) | CES2CES1CA3CA6CA5A | |
| SCHEMBL23864570 | 0.78 | ALDH1A1 (0.35) | CES2CES1HRH4ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0030716-B1 | CHLORINATED PVC BLENDS WITH IMPROVED PROCESSABILITY | The B.F. GOODRICH Company (US) | 1984-02-08 | — | — | EP | claimed |
| US-8916593-B2 | Alkoxy-substituted 2-aminopyridines as ALK inhibitors | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2009061596-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009052288-A1 | SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
| EP-1697336-B1 | AROYLFURANES AND AROYLTHIOPHENES SUITABLE FOR THE TREATMENT OF CANCER | BASILEA PHARMACEUTICA AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-0030716-B1 | CHLORINATED PVC BLENDS WITH IMPROVED PROCESSABILITY | The B.F. GOODRICH Company (US) | 1984-02-08 | — | — | EP | disclosed |
| US-4304884-A | A-ALKYLSTYRENE-VINYLBENZENE OR ACRYLATE-NITRILE TERPOLYMER | THE B. F. GOODRICH COMPANY (US) | 1981-12-08 | — | — | US | disclosed |
| EP-0030716-A1 | Chlorinated PVC blends with improved processability | The B.F. GOODRICH Company (US) | 1981-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196952-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, ACVR1 | CES2 2687/4885CES1 1172/4885CA3 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.